Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Astellas agrees licensing deal for new Optimer drug

Astellas agrees licensing deal for new Optimer drug

8th February 2011

Astellas has agreed a licensing deal to commercialise a new Clostridium difficile infection (CDI) treatment from Optimer Pharmaceuticals in Europe.

The exclusive collaboration and license agreement will see Astellas take financial responsibility for the development and sale of the investigational antibiotic fidaxomicin in a number of regions, as well as paying Optimer various milestone fees.

Fidaxomicin is an orally administered macrocyclic antibiotic which utilises a new mechanism of action to combat CDI and has had its efficacy demonstrated by data from phase III trials.

Optimer has already begun the marketing authorisation application process with the European Medicines Agency for the drug.

Masao Yoshida, president and chief executive officer of Astellas Pharma Europe, said: "We believe the combined strengths of Astellas' world-class anti-infective business capabilities … combined with Optimer's novel therapeutic for CDI represents the most effective way to address a serious, unmet health need."

Last month, Astellas announced that it is conducting a review of its strategy pertaining to its subsidiary Prosidion, with a sale of the company among the options being considered.ADNFCR-8000103-ID-800391111-ADNFCR

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.